Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China
Sponsor: Sunshine Lake Pharma Co., Ltd.
Summary
The purpose of this study is to see if Insulin Degludec/Insulin Aspart (22011) compared to Insulin Degludec/Insulin Aspart (Ryzodeg) is similar in safety and effect in participants with type 2 diabetes (T2D).
Official title: A Multi-center, Randomized, Open, Phase III Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared Efficacy and Safety With Insulin Degludec/Insulin Aspart(Ryzodeg) in Chinese Subjects With Type 2 Diabetes
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
414
Start Date
2023-07-06
Completion Date
2024-08-16
Last Updated
2026-05-01
Healthy Volunteers
No
Conditions
Interventions
Insulin Degludec and Insulin Aspart
administered subcutaneously, once a day
Locations (1)
Sunshine Lake Pharma Co., Ltd.
Dongguan, Guangdong, China